Sep. 9 at 3:31 PM
$CGEM data looks very good.....
PRINCETON, N.J. and CAMBRIDGE, Mass., Sept. 9, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced new data from the REZILIENT1 and REZILIENT2 trials of zipalertinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced or metastatic non-small cell lung cancer (NSCLC). These data will be presented at the IASLC 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer as mini oral presentations on September 9 during the "MA08 - Common and Uncommon EGFR Mutations, New Treatments in the Horizon" session, from 11:30 a.m. -- 12:45 p.m. CEST.
A mini oral presentation will highlight updated data from the pivotal Phase 2b REZILIENT1 trial of zipalertinib, focused on patients with NSCLC harboring EGFR ex20ins mutations, who have been previously treated with amivantamab.(1)
